Xencor has dosed the first patient in the DUET-2 clinical trial, a Phase l trial of XmAb20717 for the treatment of patients with selected advanced solid tumours.
A total of 87 patients are expected to be enrolled in the first-in-human, open-label, multiple-dose, dose-escalation trial.
The trial is designed to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumour activity of intravenous administration of XmAb20717 in the enrolled patients.
Xencor chief medical officer Paul Foster said: “Built on the scaffold of Xencor’s XmAb bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumour microenvironment activators.
“The dual blockade of PD-1 and CTLA-4 with XmAb20717 may promote superior T-cell activation and proliferation compared to anti-PD-1 alone, and we look forward to studying its safety, tolerability and therapeutic activity in clinical trials.”
XmAb20717 is a bispecific antibody capable of simultaneously targeting programmed death-ligand 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) immune checkpoints to treat multiple advanced solid tumours.
Xencor has so far developed 11 candidates using its XmAb technology and are currently examining the candidates under various internal and external clinical development programmes.
In addition, Xencor intends to submit investigational new drug applications for two additional tumour microenvironment activators, including XmAb23104 and XmAb22841 later this year.
XmAb23104 is a PD-1 x ICOS bispecific antibody, while XmAb22841 is a CTLA-4 x LAG-3 dual checkpoint inhibitor.